Design and Synthesis of Amino Acid Tethered Thiazolones to Screen for Hepatitis C NS5B Polymerase Inhibitors

Author(s): Yili Ding* , Kenneth L. Smith , Chamakura V.N.S. Varaprasad .

Journal Name: Letters in Drug Design & Discovery

Volume 14 , Issue 12 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Hepatitis C Virus (HCV) infection is one of the causes for liver cirrhosis and hepatocellular carcinoma leading to liver failure. An estimated 2-3% of the world population is chronically infected with HCV. HCV is a positive single stranded RNA virus encoding for a single polypeptide, which cleaves into structural and non-structural proteins. The non-structural (NS) proteins play critical roles in viral replication and have become the targets for HCV chemotherapy. The current treatment involves pegylated interferon-α/ribavirin-based treatment and a combination of direct-acting antivirals. NS5B is a critical enzyme for the replication of HCV RNA and is an interesting target for the screening and design of small molecule inhibitors to interfere in the HCV viral replication.

Methods: Screening of a library of compounds in a replicon assay, a thiazolone derivative was identified as a NS5B enzyme inhibitor (IC50: 11 µM). Based on the structure of this lead compound, few libraries of compounds were designed and synthesized following a fragment based approach. Structural features of both peptide-based and non-peptide-based protease inhibitors such as lopinavir and tipranavir were considered while designing novel compounds.

Results: Several novel protease inhibitors were designed and synthesized based on the structural fragments of lopinavir and tipranavir. This resulted in identification of compounds with thiazolone scaffold as having good anti-HCV NS5B enzyme activity.

However, to improve their cellular activity, the thiazolone scaffold was then tethered with several amino acids and then screened for their anti-HCV activity which led to finding a tethered thiazolone as novel hepatitis C NS5B polymerase inhibitor with good cellular potency (EC50 = 1.2 µM).

Conclusion: Systematic modification of lead compound (EC50 = 35 µM) from an enzyme assay and by tethering with a suitable amino acid improved the cellular potency of the lead compound. This resulted in a compound 18c with nearly 30 fold (EC50 = 1.2 µM) potent compound in cellular assay than the original lead compound. It's believed that this improvement was possible because of better transport of the active compound into the cell due to its amino acid tether.

Keywords: Amino acid, tethered thiazolone, library, hepatitis C, NS5B polymerase inhibitors, liver failure.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 12
Year: 2017
Page: [1376 - 1381]
Pages: 6
DOI: 10.2174/1570180814666170505121156
Price: $58

Article Metrics

PDF: 17